Literature DB >> 20606531

Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy.

Seiji Mabuchi1, Fumiaki Isohashi, Yasuo Yoshioka, Kumiko Temma, Takashi Takeda, Toshiya Yamamoto, Takayuki Enomoto, Kenichirou Morishige, Takehiro Inoue, Tadashi Kimura.   

Abstract

INTRODUCTION: The aim of this study was to identify the prognostic factors and to establish a model for the prediction of life expectancy in patients with recurrent cervical cancer that had previously been treated with radiotherapy.
METHODS: The records of consecutive women with recurrent cervical cancer after radiotherapy were retrospectively reviewed. Primary disease, follow-up, and recurrence data were collected. Univariate and multivariate analyses of prognostic factors of survival were performed.
RESULTS: A total of 162 patients were included in our database. The median survival after recurrence was 15 months. Multivariate analysis revealed that symptom status, the site of relapse, prior chemoradiotherapy, and treatment modality were significant prognostic factors in terms of survival after recurrence. Patient survival was inversely correlated with the number of these prognostic factors. When the patients were divided into 3 prognostic groups, (low risk: patients with no poor prognostic factors; intermediate: patients with one poor prognostic factor; and high-risk: patients with more than 2 poor prognostic factors), the patients in the high-risk group had a significantly shorter survival (median, 10 months) than those with one risk factor (median, 20 months) or no risk factors (median, 36 months).
CONCLUSIONS: Symptom status, the site of relapse, prior chemoradiotherapy, and treatment modality are significant prognostic factors in patients with recurrent cervical cancer that had previously been treated with radiotherapy. Our prognostic model, composed of 4 clinical variables, may enable physicians to predict survival more accurately.

Entities:  

Mesh:

Year:  2010        PMID: 20606531     DOI: 10.1111/IGC.0b013e3181dcadd1

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  16 in total

1.  A post-recurrence survival-predicting indicator for cervical cancer from the analysis of 165 patients who developed recurrence.

Authors:  Kosuke Yoshida; Hiroaki Kajiyama; Fumi Utsumi; Kaoru Niimi; Jun Sakata; Shiro Suzuki; Kiyosumi Shibata; Fumitaka Kikkawa
Journal:  Mol Clin Oncol       Date:  2017-12-08

2.  The upregulated expression of vascular endothelial growth factor in surgically treated patients with recurrent/radioresistant cervical cancer of the uterus.

Authors:  Kosuke Yoshida; Shiro Suzuki; Jun Sakata; Fumi Utsumi; Kaoru Niimi; Nobuhisa Yoshikawa; Kimihiro Nishino; Kiyosumi Shibata; Fumitaka Kikkawa; Hiroaki Kajiyama
Journal:  Oncol Lett       Date:  2018-05-02       Impact factor: 2.967

3.  The efficacy of surgical treatment of recurrent or persistent cervical cancer that develops in a previously irradiated field: a monoinstitutional experience.

Authors:  Seiji Mabuchi; Yuri Matsumoto; Naoko Komura; Masaaki Sawada; Mie Tanaka; Eriko Yokoi; Katsumi Kozasa; Akihiko Yoshimura; Hiromasa Kuroda; Tadashi Kimura
Journal:  Int J Clin Oncol       Date:  2017-05-27       Impact factor: 3.402

4.  Patient age, tumor appearance and tumor size are risk factors for early recurrence of cervical cancer.

Authors:  Juan Wang; Tao Wang; Yun-Yi Yang; Yan-Lan Chai; Fan Shi; Z I Liu
Journal:  Mol Clin Oncol       Date:  2014-11-24

5.  Efficacy of Modified Dose-dense Paclitaxel in Recurrent Cervical Cancer.

Authors:  Hiroko Machida; Aida Moeini; Marcia A Ciccone; Sayedamin Mostofizadeh; Tsuyoshi Takiuchi; Laurie L Brunette; Lynda D Roman; Koji Matsuo
Journal:  Am J Clin Oncol       Date:  2018-09       Impact factor: 2.339

6.  3D radiation therapy or intensity-modulated radiotherapy for recurrent and metastatic cervical cancer: the Shanghai Cancer Hospital experience.

Authors:  Su-Ping Liu; Xiao Huang; Gui-Hao Ke; Xiao-Wei Huang
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

7.  Bone recurrence after radical hysterectomy and lymphadenectomy in early-stage cervical cancer.

Authors:  Caner Çakır; Dilek Yüksel; Çiğdem Kılıç; Mehmet Ünsal; Rıza Dur; Gökhan Boyraz; Alper Karalok; Özlem Moraloğlu Tekin; Taner Turan
Journal:  Turk J Obstet Gynecol       Date:  2020-02-28

8.  Utility of risk-weighted surgical-pathological factors in early-stage cervical cancer.

Authors:  K Matsuo; S Mabuchi; M Okazawa; Y Matsumoto; T Tsutsui; M Fujita; S Kamiura; K Ogawa; C P Morrow; T Kimura
Journal:  Br J Cancer       Date:  2013-03-05       Impact factor: 7.640

9.  Utility of serum squamous cell carcinoma antigen levels at the time of recurrent cervical cancer diagnosis in determining the optimal treatment choice.

Authors:  Kotaro Shimura; Seiji Mabuchi; Takeshi Yokoi; Tomoyuki Sasano; Kenjirou Sawada; Toshimitsu Hamasaki; Tadashi Kimura
Journal:  J Gynecol Oncol       Date:  2013-10-02       Impact factor: 4.401

10.  Continuous low-dose oral chemotherapy in recurrent and persistent carcinoma of cervix following chemoradiation: a comparative study between prolonged oral cyclophosphamide and oral Etoposide.

Authors:  Upasana Baruah; Debabrata Barmon; Munlima Hazarika; Pankaj Deka; Amal Chandra Kataki; Sushruta Shrivastava
Journal:  Indian J Palliat Care       Date:  2014-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.